Since weight-loss drugs that target the hormone GLP-1 have surged in popularity, some additional health benefits have emerged. Beyond helping people shed pounds, they also lower the risk of heart disease and sleep apnea—and the U.

Health experts are investigating a possible link between popular weight loss drugs like Ozempic and sudden blindness.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol cravings and consumption.